New Immunotherapy Platform Deploys Engineered Molecules to Inhibit SARS-CoV-2 Infection and Remove COVID-19 Infected Cells

A pioneering immunotherapy platform that deploys engineered proprietary molecules to create synthetic immunity could aid in the fight against COVID-19.

Anna Biosciences (Dublin, Ireland), a drug discovery company focused on novel therapies in immuno-oncology, virology, and neurodegenerative diseases, has introduced its immunotherapy platform, Syntem. The Anna Biosciences Syntem Platform deploys engineered proprietary molecules to create synthetic immunity. Syntem’s lab-made molecules are multi-specific: they first target and flag the pathology, and then elicit an immune reaction that targets the virus or disease.


Research indicates the Syntem Platform can inhibit viral infection and aid in the removal of COVID-19 infected cells. Showing promise as both a prophylactic and a treatment, there is considerable hope that in addition to supporting the broader population, immune-compromised patients will be able to safely use Syntem to prevent infection. Importantly, Syntem also exhibits high potential against COVID variants. In the case of COVID-19, and coronaviruses more generally, the Syntem Platform represents a significant new tool in the arsenal against these rapidly evolving diseases.

“Like vaccines in the 20th century, synthetic small molecule immunotherapy is on the precipice of advancing human health in untold ways. A powerful new tool is on the horizon in our fight against coronaviruses. And that’s just the beginning of this technology’s potential,” said Dr. Anthony Rullo, a scientific co-founder of Anna Biosciences and assistant professor of medicine at McMaster University.

Related Links:
Anna Biosciences